scholarly journals Preoperative Albumin–Bilirubin Grade With Prognostic Nutritional Index Predicts the Outcome of Patients With Early-Stage Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation

2020 ◽  
Vol 7 ◽  
Author(s):  
Jingying Pan ◽  
Shuochun Chen ◽  
Guo Tian ◽  
Tianan Jiang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Early Stage ◽  
Prognostic Nutritional Index ◽  
Percutaneous Radiofrequency Ablation ◽  
Nutritional Index ◽  
Preoperative Albumin

Percutaneous radiofrequency ablation for the treatment of early stage hepatocellular carcinoma: A health technology assessment

2010 ◽  
Vol 26 (4) ◽  
pp. 390-397 ◽  
Author(s):  
Xuanqian Xie ◽  
Nandini Dendukuri ◽  
Maurice McGregor
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Survival Rate ◽  
Cohort Studies ◽  
Early Stage ◽  
Disease Free Survival ◽  
Sufficient Evidence ◽  
Percutaneous Radiofrequency Ablation ◽  
Free Survival ◽  
Disease Free

Objectives: The aim of this study was to compare the clinical effectiveness and cost of percutaneous radiofrequency ablation (PRFA) and surgical resection (SRS) for the management of early stage Hepatocellular Carcinoma.Methods: A systematic literature search of articles in English, French, and Chinese was performed using online databases. Only articles with patients classified as Child-Pugh Class A or B, with tumor size <5 cm were included. A meta-analysis was carried out to estimate the survival rate and disease-free survival rate following PRFA or SRS treatments. The cost of each treatment was estimated from the third party perspective. Univariate sensitivity analyses were used to study the relative importance of each component cost.Results: We identified six studies (one randomized controlled trial (RCT) and five comparative cohort studies) meeting our inclusion criteria. There is good evidence that among Child-Pugh A patients for whom both SRS and PRFA are available options, survival rates following either procedure are comparable, while complications are more frequent and hospitalization longer following SRS. The evidence concerning recurrence rates and disease-free survival is less clear. Whereas the RCT indicates comparable outcomes with either procedure up to 3 years, the results of five cohort studies (with possible selection bias), particularly those with a mix of Child-Pugh A and B patients, favor the surgical option. SRS, costs approximately Canadian $8,275 more per case than PRFA.Conclusions: Continuing doubts on this issue can only be resolved by a substantial RCT. Meanwhile, for early stage HCC patients classified as Child-Pugh A, who despite a possibly higher recurrence rate, prefer the less invasive PRFA to open surgery with its attendant risks, there is sufficient evidence to justify such a choice. For those classified as Child-Pugh (B) it is possible that overall survival is equally good with PRFA, but the evidence is less certain.

Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection

2015 ◽  
Vol 22 (13) ◽  
pp. 4138-4148 ◽  
Author(s):  
Anthony W. H. Chan ◽  
Stephen L. Chan ◽  
Grace L. H. Wong ◽  
Vincent W. S. Wong ◽  
Charing C. N. Chong ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Surgical Resection ◽  
Tumor Recurrence ◽  
Early Stage ◽  
Prognostic Nutritional Index ◽  
Nutritional Index

scholarly journals Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Early-stage Hepatocellular Carcinoma: A Propensity Score-matched Analysis

2021 ◽  
Author(s):  
Kota Takaki ◽  
Masahito Nakano ◽  
Kazuta Fukumori ◽  
Yoichi Yano ◽  
Yuki Zaizen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Propensity Score ◽  
Tumor Size ◽  
Multivariate Analyses ◽  
Early Stage ◽  
Significant Prognostic Factor ◽  
Percutaneous Radiofrequency Ablation ◽  
Central Hospital ◽  
Significant Difference

We aimed to compare prognostic factors for overall survival (OS) following percutaneous radiofrequency ablation (PRFA) with or without chemolipiodolization (CL) for early-stage hepatocellular carcinoma (HCC) using propensity score-matched analysis. We enrolled 221 patients with early-stage HCC who received PRFA with (n = 76) or without (n = 145) CL in Saga Central Hospital between April 2004 and December 2020. No significant difference was observed in OS between PRFA with and without CL cohorts (median survival time [MST]: 5.4 vs. 4.5 years; p = 0.0806). To reduce confounding effects, 108 patients were selected using propensity score-matched analysis (n = 54 for each treatment). No significant difference was observed in OS between the cohorts (MST: 3.6 vs. 4.0 years; p = 0.5474). After stratification according to tumor size, no significant difference was observed in OS for patients with tumor size ≥20 mm between PRFA with and without CL cohorts (MST: 3.4 vs. 3.5 years; p = 0.8236). PRFA with CL was not a significant prognostic factor in both univariate and multivariate analyses (p = 0.5477 and 0.9600, respectively). Our findings suggest that PRFA with CL does not demonstrate longer prognostic effects than PRFA without CL in early-stage HCC, regardless of tumor size.

Leberzellkarzinom – Radiofrequenzablation: Welches Bildgebungsverfahren ist effektiver?

2019 ◽  
Vol 24 (04) ◽  
pp. 163-164
Author(s):  
Cornelia Fietz
Keyword(s):  
Computed Tomography ◽  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Comparative Effectiveness ◽  
Percutaneous Radiofrequency Ablation ◽  
Ultrasound Guided ◽  
Medicare Patients ◽  
Us Dollar

Huo J et al. Comparative Effectiveness of Computed Tomography-Versus Ultrasound-Guided Percutaneous Radiofrequency Ablation Among Medicare Patients 65 Years of Age or Older With Hepatocellular Carcinoma. Value Health 2019; 22(3):284–292 Die Inzidenz des Leberzellkarzinoms hat sich in den letzen 20 Jahren mehr als verdoppelt. 2018 wurden in den USA mehr als 31 600 neue Fälle registriert, knapp die Hälfte dieser Patienten war älter als 65 Jahre. Die damit verbundenen jährlichen Kosten werden auf 455 Millionen US Dollar geschätzt. Für fortgeschrittene, inoperable Fälle steht die Radiofrequenzablation als Therapieoption zur Verfügung, die Ultraschall- oder Computertomographie-gestützt durchgeführt werden kann. Die Autoren vergleichen die Effektivität beider Bildgebungstechniken für das Verfahren.

Sign in / Sign up

Export Citation Format

Share Document